Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02406521 · ClinicalTrials.gov registry record · Phase 1
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02406521 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants.
The verdict
NCT02406521, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This research study is comparing different drug combinations as a possible treatment for metastatic renal cell carcinoma (mRCC) and bone metastases. The names of the study interventions involved in this study are: * Combination of Radium-223 and Sorafenib * Combination of Radium-223 and Pazopanib
Interventions
- DRUG Sorafenib
- DRUG Pazopanib
- DRUG Radium-223
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02406521
The ClinicalTrials.gov registry entry for NCT02406521 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sorafenib is the first listed.
NCT02406521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02406521 about?
NCT02406521 is a clinical study titled "Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets". This research study is comparing different drug combinations as a possible treatment for metastatic renal cell carcinoma (mRCC) and bone metastases. The names of the study interventions involved in this study are: * Combination of Radium-223 and Sorafenib * Combination of Radium-223 and Pazopanib
What is the current status of trial NCT02406521?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-04. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT02406521?
The interventions under investigation include: Sorafenib (DRUG), Pazopanib (DRUG), Radium-223 (DRUG).
Who is sponsoring clinical trial NCT02406521?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.